PepJunkie Home of the Peptonauts
More
HomeThe PulseAtlasDiscussHunter-GathererResearchProfileSearch

Research

Vesugen — living evidence map

The Atlas page holds the claims; this is how its evidence evolved.

Summary

The tripeptide Lys-Glu-Asp stimulated proliferation and inhibited apoptosis in organotypic cultures of neuroimmunoendocrine cells, with a stronger effect in cultures from old animals. · pmid:22977872

Mechanism

A 2022 review lists the KED tripeptide among vasoprotective peptides that regulate molecules of the senescence-associated secretory phenotype in cardiovascular cells. · pmid:36611900

Identity

PubChem CID 87571363: Lysyl-glutamyl-aspartic acid, C15H26N4O8, 390.39 g/mol. · pubchem:87571363

CAS registry number 204271-66-9. · pubchem:87571363

IUPAC name: (2S)-2-[[(2S)-4-carboxy-2-[[(2S)-2,6-diaminohexanoyl]amino]butanoyl]amino]butanedioic acid. · pubchem:87571363

Where the evidence actually sits

Preclinical only100%

Proportion of the 2 claims about Vesugen standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.

Living evidence history

Effect of tripeptide Lys-Glu-Asp on physiological activity of neuroimmunoendocrine system cells. (2012) · preclinicalSenescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation. (2022) · preclinical20122022

2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.

Structure

No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Vesugen yet.

Dose evidence, rung by rung

No established safe human dose. Nothing on file establishes one. That is a statement about the evidence PepJunkie holds, not a promise about the molecule.

  1. Approved-label dose · a resolved regulatory document names a labelled dose

    nothing resolved on this rung

  2. Studied human doses · resolved human studies at the established tier

    nothing resolved on this rung

  3. Observational evidence · resolved human data at the emerging tier: thin, or contested

    nothing resolved on this rung

  4. Community-reported protocols · protocol propositions from distinct members, counted once per human

    nothing resolved on this rung

  5. Preclinical evidence · resolved animal, cell or mechanistic work
    • Effect of tripeptide Lys-Glu-Asp on physiological activity of neuroimmunoendocrine system cells. · pmid 22977872 · 2012
    • Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation. · pmid 36611900 · 2022

2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.